The Predictive Value of Coronary Artery Calcium Scoring for Major Adverse Cardiac Events According to Renal Function (from the Coronary Computed Tomography Angiography Evaluation for Clinical Outcomes: An International Multicenter [CONFIRM] Registry)

Ji Hyun Lee, Asim Rizvi, Bríain Hartaigh, Donghee Han, Mahn Won Park, Hadi Mirhedayati Roudsari, Wijnand J. Stuijfzand, Heidi Gransar, Yao Lu, Tracy Q. Callister, Daniel S. Berman, Augustin DeLago, Martin Hadamitzky, Joerg Hausleiter, Mouaz H. Al-Mallah, Matthew J. Budoff, Philipp A. Kaufmann, Gilbert L. Raff, Kavitha Chinnaiyan, Filippo CademartiriErica Maffei, Todd C. Villines, Yong Jin Kim, Jonathon Leipsic, Gudrun Feuchtner, Gianluca Pontone, Daniele Andreini, Hugo Marques, Pedro de Araújo Gonçalves, Ronen Rubinshtein, Stephan Achenbach, Leslee J. Shaw, Benjamin J.W. Chow, Ricardo C. Cury, Jeroen J. Bax, Hyuk-Jae Chang, Erica C. Jones, Fay Y. Lin, James K. Min, Jessica M. Peña

Research output: Contribution to journalArticle

Abstract

The prognostic performance of coronary artery calcium score (CACS) for predicting adverse outcomes in patients with decreased renal function remains unclear. We aimed to examine whether CACS improves risk stratification by demonstrating incremental value beyond a traditional risk score according to renal function status. 9,563 individuals without known coronary artery disease were enrolled. Estimated glomerular filtration rate (eGFR, ml/min/1.73 m 2 ) was ascertained using the modified Modification of Diet in Renal Disease formula, and was categorized as: ≥90, 60 to 89, and <60. CACS was categorized as 0, 1 to 100, 101 to 400, and >400. Multivariable Cox regression was used to estimate hazard ratios (HR) with 95% confidence intervals (95% CI) for major adverse cardiac events (MACE), comprising all-cause mortality, myocardial infarction, and late revascularization (>90 days). Mean age was 55.8 ± 11.5 years (52.8% male). In total, 261 (2.7%) patients experienced MACE over a median follow-up of 24.5 months (interquartile range: 16.9 to 41.1). Incident MACE increased with higher CACS across each eGFR category, with the highest rate observed among patients with CACS >400 and eGFR <60 (95.1 per 1,000 person-years). A CACS >400 increased MACE risk with HR 4.46 (95% CI 1.68 to 11.85), 6.63 (95% CI 4.03 to 10.92), and 6.14 (95% CI 2.85 to 13.21) for eGFR ≥90, 60 to 89, and <60, respectively, as compared with CACS 0. Further, CACS improved discrimination and reclassification beyond Framingham 10-year risk score (FRS) (AUC: 0.70 vs 0.64; category free-NRI: 0.51, all p <0.001) for predicting MACE in patients with impaired renal function (eGFR < 90). In conclusion, CACS improved risk stratification and provided incremental value beyond FRS for predicting MACE, irrespective of eGFR status.

Original languageEnglish
Pages (from-to)1435-1442
Number of pages8
JournalAmerican Journal of Cardiology
Volume123
Issue number9
DOIs
Publication statusPublished - 2019 May 1

Fingerprint

Registries
Coronary Vessels
Calcium
Kidney
Confidence Intervals
Diet Therapy
Computed Tomography Angiography
Glomerular Filtration Rate
Area Under Curve
Coronary Artery Disease
Myocardial Infarction
Mortality

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Lee, Ji Hyun ; Rizvi, Asim ; Hartaigh, Bríain ; Han, Donghee ; Park, Mahn Won ; Roudsari, Hadi Mirhedayati ; Stuijfzand, Wijnand J. ; Gransar, Heidi ; Lu, Yao ; Callister, Tracy Q. ; Berman, Daniel S. ; DeLago, Augustin ; Hadamitzky, Martin ; Hausleiter, Joerg ; Al-Mallah, Mouaz H. ; Budoff, Matthew J. ; Kaufmann, Philipp A. ; Raff, Gilbert L. ; Chinnaiyan, Kavitha ; Cademartiri, Filippo ; Maffei, Erica ; Villines, Todd C. ; Kim, Yong Jin ; Leipsic, Jonathon ; Feuchtner, Gudrun ; Pontone, Gianluca ; Andreini, Daniele ; Marques, Hugo ; de Araújo Gonçalves, Pedro ; Rubinshtein, Ronen ; Achenbach, Stephan ; Shaw, Leslee J. ; Chow, Benjamin J.W. ; Cury, Ricardo C. ; Bax, Jeroen J. ; Chang, Hyuk-Jae ; Jones, Erica C. ; Lin, Fay Y. ; Min, James K. ; Peña, Jessica M. / The Predictive Value of Coronary Artery Calcium Scoring for Major Adverse Cardiac Events According to Renal Function (from the Coronary Computed Tomography Angiography Evaluation for Clinical Outcomes : An International Multicenter [CONFIRM] Registry). In: American Journal of Cardiology. 2019 ; Vol. 123, No. 9. pp. 1435-1442.
@article{8187c711855f4d1e99d95a693777e046,
title = "The Predictive Value of Coronary Artery Calcium Scoring for Major Adverse Cardiac Events According to Renal Function (from the Coronary Computed Tomography Angiography Evaluation for Clinical Outcomes: An International Multicenter [CONFIRM] Registry)",
abstract = "The prognostic performance of coronary artery calcium score (CACS) for predicting adverse outcomes in patients with decreased renal function remains unclear. We aimed to examine whether CACS improves risk stratification by demonstrating incremental value beyond a traditional risk score according to renal function status. 9,563 individuals without known coronary artery disease were enrolled. Estimated glomerular filtration rate (eGFR, ml/min/1.73 m 2 ) was ascertained using the modified Modification of Diet in Renal Disease formula, and was categorized as: ≥90, 60 to 89, and <60. CACS was categorized as 0, 1 to 100, 101 to 400, and >400. Multivariable Cox regression was used to estimate hazard ratios (HR) with 95{\%} confidence intervals (95{\%} CI) for major adverse cardiac events (MACE), comprising all-cause mortality, myocardial infarction, and late revascularization (>90 days). Mean age was 55.8 ± 11.5 years (52.8{\%} male). In total, 261 (2.7{\%}) patients experienced MACE over a median follow-up of 24.5 months (interquartile range: 16.9 to 41.1). Incident MACE increased with higher CACS across each eGFR category, with the highest rate observed among patients with CACS >400 and eGFR <60 (95.1 per 1,000 person-years). A CACS >400 increased MACE risk with HR 4.46 (95{\%} CI 1.68 to 11.85), 6.63 (95{\%} CI 4.03 to 10.92), and 6.14 (95{\%} CI 2.85 to 13.21) for eGFR ≥90, 60 to 89, and <60, respectively, as compared with CACS 0. Further, CACS improved discrimination and reclassification beyond Framingham 10-year risk score (FRS) (AUC: 0.70 vs 0.64; category free-NRI: 0.51, all p <0.001) for predicting MACE in patients with impaired renal function (eGFR < 90). In conclusion, CACS improved risk stratification and provided incremental value beyond FRS for predicting MACE, irrespective of eGFR status.",
author = "Lee, {Ji Hyun} and Asim Rizvi and Br{\'i}ain Hartaigh and Donghee Han and Park, {Mahn Won} and Roudsari, {Hadi Mirhedayati} and Stuijfzand, {Wijnand J.} and Heidi Gransar and Yao Lu and Callister, {Tracy Q.} and Berman, {Daniel S.} and Augustin DeLago and Martin Hadamitzky and Joerg Hausleiter and Al-Mallah, {Mouaz H.} and Budoff, {Matthew J.} and Kaufmann, {Philipp A.} and Raff, {Gilbert L.} and Kavitha Chinnaiyan and Filippo Cademartiri and Erica Maffei and Villines, {Todd C.} and Kim, {Yong Jin} and Jonathon Leipsic and Gudrun Feuchtner and Gianluca Pontone and Daniele Andreini and Hugo Marques and {de Ara{\'u}jo Gon{\cc}alves}, Pedro and Ronen Rubinshtein and Stephan Achenbach and Shaw, {Leslee J.} and Chow, {Benjamin J.W.} and Cury, {Ricardo C.} and Bax, {Jeroen J.} and Hyuk-Jae Chang and Jones, {Erica C.} and Lin, {Fay Y.} and Min, {James K.} and Pe{\~n}a, {Jessica M.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.amjcard.2019.01.055",
language = "English",
volume = "123",
pages = "1435--1442",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "9",

}

Lee, JH, Rizvi, A, Hartaigh, B, Han, D, Park, MW, Roudsari, HM, Stuijfzand, WJ, Gransar, H, Lu, Y, Callister, TQ, Berman, DS, DeLago, A, Hadamitzky, M, Hausleiter, J, Al-Mallah, MH, Budoff, MJ, Kaufmann, PA, Raff, GL, Chinnaiyan, K, Cademartiri, F, Maffei, E, Villines, TC, Kim, YJ, Leipsic, J, Feuchtner, G, Pontone, G, Andreini, D, Marques, H, de Araújo Gonçalves, P, Rubinshtein, R, Achenbach, S, Shaw, LJ, Chow, BJW, Cury, RC, Bax, JJ, Chang, H-J, Jones, EC, Lin, FY, Min, JK & Peña, JM 2019, 'The Predictive Value of Coronary Artery Calcium Scoring for Major Adverse Cardiac Events According to Renal Function (from the Coronary Computed Tomography Angiography Evaluation for Clinical Outcomes: An International Multicenter [CONFIRM] Registry)', American Journal of Cardiology, vol. 123, no. 9, pp. 1435-1442. https://doi.org/10.1016/j.amjcard.2019.01.055

The Predictive Value of Coronary Artery Calcium Scoring for Major Adverse Cardiac Events According to Renal Function (from the Coronary Computed Tomography Angiography Evaluation for Clinical Outcomes : An International Multicenter [CONFIRM] Registry). / Lee, Ji Hyun; Rizvi, Asim; Hartaigh, Bríain; Han, Donghee; Park, Mahn Won; Roudsari, Hadi Mirhedayati; Stuijfzand, Wijnand J.; Gransar, Heidi; Lu, Yao; Callister, Tracy Q.; Berman, Daniel S.; DeLago, Augustin; Hadamitzky, Martin; Hausleiter, Joerg; Al-Mallah, Mouaz H.; Budoff, Matthew J.; Kaufmann, Philipp A.; Raff, Gilbert L.; Chinnaiyan, Kavitha; Cademartiri, Filippo; Maffei, Erica; Villines, Todd C.; Kim, Yong Jin; Leipsic, Jonathon; Feuchtner, Gudrun; Pontone, Gianluca; Andreini, Daniele; Marques, Hugo; de Araújo Gonçalves, Pedro; Rubinshtein, Ronen; Achenbach, Stephan; Shaw, Leslee J.; Chow, Benjamin J.W.; Cury, Ricardo C.; Bax, Jeroen J.; Chang, Hyuk-Jae; Jones, Erica C.; Lin, Fay Y.; Min, James K.; Peña, Jessica M.

In: American Journal of Cardiology, Vol. 123, No. 9, 01.05.2019, p. 1435-1442.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The Predictive Value of Coronary Artery Calcium Scoring for Major Adverse Cardiac Events According to Renal Function (from the Coronary Computed Tomography Angiography Evaluation for Clinical Outcomes

T2 - An International Multicenter [CONFIRM] Registry)

AU - Lee, Ji Hyun

AU - Rizvi, Asim

AU - Hartaigh, Bríain

AU - Han, Donghee

AU - Park, Mahn Won

AU - Roudsari, Hadi Mirhedayati

AU - Stuijfzand, Wijnand J.

AU - Gransar, Heidi

AU - Lu, Yao

AU - Callister, Tracy Q.

AU - Berman, Daniel S.

AU - DeLago, Augustin

AU - Hadamitzky, Martin

AU - Hausleiter, Joerg

AU - Al-Mallah, Mouaz H.

AU - Budoff, Matthew J.

AU - Kaufmann, Philipp A.

AU - Raff, Gilbert L.

AU - Chinnaiyan, Kavitha

AU - Cademartiri, Filippo

AU - Maffei, Erica

AU - Villines, Todd C.

AU - Kim, Yong Jin

AU - Leipsic, Jonathon

AU - Feuchtner, Gudrun

AU - Pontone, Gianluca

AU - Andreini, Daniele

AU - Marques, Hugo

AU - de Araújo Gonçalves, Pedro

AU - Rubinshtein, Ronen

AU - Achenbach, Stephan

AU - Shaw, Leslee J.

AU - Chow, Benjamin J.W.

AU - Cury, Ricardo C.

AU - Bax, Jeroen J.

AU - Chang, Hyuk-Jae

AU - Jones, Erica C.

AU - Lin, Fay Y.

AU - Min, James K.

AU - Peña, Jessica M.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The prognostic performance of coronary artery calcium score (CACS) for predicting adverse outcomes in patients with decreased renal function remains unclear. We aimed to examine whether CACS improves risk stratification by demonstrating incremental value beyond a traditional risk score according to renal function status. 9,563 individuals without known coronary artery disease were enrolled. Estimated glomerular filtration rate (eGFR, ml/min/1.73 m 2 ) was ascertained using the modified Modification of Diet in Renal Disease formula, and was categorized as: ≥90, 60 to 89, and <60. CACS was categorized as 0, 1 to 100, 101 to 400, and >400. Multivariable Cox regression was used to estimate hazard ratios (HR) with 95% confidence intervals (95% CI) for major adverse cardiac events (MACE), comprising all-cause mortality, myocardial infarction, and late revascularization (>90 days). Mean age was 55.8 ± 11.5 years (52.8% male). In total, 261 (2.7%) patients experienced MACE over a median follow-up of 24.5 months (interquartile range: 16.9 to 41.1). Incident MACE increased with higher CACS across each eGFR category, with the highest rate observed among patients with CACS >400 and eGFR <60 (95.1 per 1,000 person-years). A CACS >400 increased MACE risk with HR 4.46 (95% CI 1.68 to 11.85), 6.63 (95% CI 4.03 to 10.92), and 6.14 (95% CI 2.85 to 13.21) for eGFR ≥90, 60 to 89, and <60, respectively, as compared with CACS 0. Further, CACS improved discrimination and reclassification beyond Framingham 10-year risk score (FRS) (AUC: 0.70 vs 0.64; category free-NRI: 0.51, all p <0.001) for predicting MACE in patients with impaired renal function (eGFR < 90). In conclusion, CACS improved risk stratification and provided incremental value beyond FRS for predicting MACE, irrespective of eGFR status.

AB - The prognostic performance of coronary artery calcium score (CACS) for predicting adverse outcomes in patients with decreased renal function remains unclear. We aimed to examine whether CACS improves risk stratification by demonstrating incremental value beyond a traditional risk score according to renal function status. 9,563 individuals without known coronary artery disease were enrolled. Estimated glomerular filtration rate (eGFR, ml/min/1.73 m 2 ) was ascertained using the modified Modification of Diet in Renal Disease formula, and was categorized as: ≥90, 60 to 89, and <60. CACS was categorized as 0, 1 to 100, 101 to 400, and >400. Multivariable Cox regression was used to estimate hazard ratios (HR) with 95% confidence intervals (95% CI) for major adverse cardiac events (MACE), comprising all-cause mortality, myocardial infarction, and late revascularization (>90 days). Mean age was 55.8 ± 11.5 years (52.8% male). In total, 261 (2.7%) patients experienced MACE over a median follow-up of 24.5 months (interquartile range: 16.9 to 41.1). Incident MACE increased with higher CACS across each eGFR category, with the highest rate observed among patients with CACS >400 and eGFR <60 (95.1 per 1,000 person-years). A CACS >400 increased MACE risk with HR 4.46 (95% CI 1.68 to 11.85), 6.63 (95% CI 4.03 to 10.92), and 6.14 (95% CI 2.85 to 13.21) for eGFR ≥90, 60 to 89, and <60, respectively, as compared with CACS 0. Further, CACS improved discrimination and reclassification beyond Framingham 10-year risk score (FRS) (AUC: 0.70 vs 0.64; category free-NRI: 0.51, all p <0.001) for predicting MACE in patients with impaired renal function (eGFR < 90). In conclusion, CACS improved risk stratification and provided incremental value beyond FRS for predicting MACE, irrespective of eGFR status.

UR - http://www.scopus.com/inward/record.url?scp=85062357187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062357187&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2019.01.055

DO - 10.1016/j.amjcard.2019.01.055

M3 - Article

C2 - 30850210

AN - SCOPUS:85062357187

VL - 123

SP - 1435

EP - 1442

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 9

ER -